Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gumarontinib - Haihe Biopharma

Next Previous
Drug Profile

Gumarontinib - Haihe Biopharma

Alternative Names: Glumetinib; Haiyitan; SCC-244

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator HaiHe Biopharma
  • Developer CSPC Pharmaceutical Group; HaiHe Biopharma
  • Class Antineoplastics; Imidazoles; Pyrazoles; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 27 Apr 2025 CSPC Pharmaceutical Group plans a phase-II trial for Solid tumours (Late-stage disease, Combination therapy) (IV), (NCT06947291)
  • 03 Apr 2025 Phase-III clinical trials in Non-small cell lung cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in China (PO) (NCT06829459)
  • 01 Apr 2025 Shanghai JMT-Bio plans a phase II/III trial for Non-small cell lung cancer (Recurrent, Metastatic disease, First-Line therapy, Combination therapy, Late-stage disease) (PO, Tablet) in April 2025 (NCT06908772)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top